Medgenics, Inc. (NYSEMKT:MDGN)

zzlangerhans (99.79) Submitted: 3/21/2013 1:26:10 AM : Start Price: $4.98 MDGN Score: -22.91

I'm as skeptical as anyone about the long-term prospects of Medgenics. For a technology as groundbreaking as the Biopump would seem to be, there doesn't seem to be much excitement coming from anyone except management. And if the company does indeed have the capabilities they say they have, they have only themselves to blame for releasing so little detail that the skeptics have been able to drown out the optimists. Getting dumped by Baxter and pumped by Ray Dirks haven't been ideal developments either.

The recent 29M dilutive financing removes one major overhang to owning the stock. I don't see interferon and erythropoietin as the best targets for this type of technology, but that's what we have now that the Factor VIII Biopump is on hold due to the Baxter rejection.If the company follows its pattern of self-promotion and avoids attracting much vitriol from the skeptics, I see a potential return to the 7 or 8 level in 2013.